Open Innovation Platform and Portfolio
60° Pharmaceuticals, LLC (60P) has embraced an open innovation platform to generate intellectual property and build our portfolio. We have or are collaborating with leading research institutions in the United States, Australia, Singapore and Italy to discover and develop oral medications for dengue fever and malaria prevention. We are about to commence a Phase II clinical development campaign for two drug candidates for dengue, a platelet activating factor receptor antagonist (60P002), and an alpha glucosidase I inhibitor (60P001), and are exploring the utility of a third (60P004, a retinoid). We are also preparing for commercial launch of 60P003 for malaria prevention in 2018, following the completion of a cooperative research and development agreement with the U.S. Army.